HomeCompareVSTKF vs PFE

VSTKF vs PFE: Dividend Comparison 2026

VSTKF yields 100.76% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VSTKF wins by $3.97M in total portfolio value
10 years
VSTKF
VSTKF
● Live price
100.76%
Share price
$1.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.02M
Annual income
$1,360,845.34
Full VSTKF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — VSTKF vs PFE

📍 VSTKF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVSTKFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VSTKF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VSTKF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VSTKF
Annual income on $10K today (after 15% tax)
$8,564.23/yr
After 10yr DRIP, annual income (after tax)
$1,156,718.54/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, VSTKF beats the other by $1,134,398.64/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VSTKF + PFE for your $10,000?

VSTKF: 50%PFE: 50%
100% PFE50/50100% VSTKF
Portfolio after 10yr
$2.03M
Annual income
$693,552.03/yr
Blended yield
34.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

VSTKF
No analyst data
Altman Z
3.7
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VSTKF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVSTKFPFE
Forward yield100.76%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.02M$49.6K
Annual income after 10y$1,360,845.34$26,258.71
Total dividends collected$3.59M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VSTKF vs PFE ($10,000, DRIP)

YearVSTKF PortfolioVSTKF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$20,776$10,075.57$9,153$693.39+$11.6KVSTKF
2$41,793$19,563.14$8,593$849.25+$33.2KVSTKF
3$81,498$36,779.47$8,336$1,066.78+$73.2KVSTKF
4$154,232$67,029.34$8,437$1,384.80+$145.8KVSTKF
5$283,581$118,552.13$9,013$1,875.40+$274.6KVSTKF
6$507,148$203,716.90$10,306$2,680.72+$496.8KVSTKF
7$883,136$340,487.85$12,820$4,101.38+$870.3KVSTKF
8$1,499,085$554,128.88$17,673$6,826.70+$1.48MVSTKF
9$2,483,095$879,074.03$27,543$12,591.86+$2.46MVSTKF
10$4,017,757$1,360,845.34$49,560$26,258.71+$3.97MVSTKF

VSTKF vs PFE: Complete Analysis 2026

VSTKFStock

VNV Global AB (publ) formerly known as Vostok New Ventures Ltd., is a private equity and venture capital firm specializing in growth capital, buyout investments, incubation, seed/startup, early venture, mid venture, late venture. It prefers to invest globally including Africa / Middle East, European Emerging Markets, Latin America and Caribbean, United States and Canada except China in online marketplaces, consumer-focused and business 2 business companies. It usually seeks investments where it can become a significant minority shareholder and actively manage the investment through board representation. The firm prefers to invest in unlisted companies. It prefers to take majority and minority stake in its portfolio companies. VNV Global AB (publ) was founded on April 5, 2007 and is based in Stockholm, Sweden with an additional office in Hamilton, Bermuda.

Full VSTKF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this VSTKF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VSTKF vs SCHDVSTKF vs JEPIVSTKF vs OVSTKF vs KOVSTKF vs MAINVSTKF vs JNJVSTKF vs MRKVSTKF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.